|

New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival

long-term peritoneal mesothelioma survivalOne of the nation’s top mesothelioma doctors says long-term peritoneal mesothelioma survival is possible with a far-reaching new surgical technique.

Dr. Paul Sugarbaker is a surgeon with the Washington Cancer Institute in Washington, DC. He has studied peritoneal mesothelioma for decades. 

In a new report, he outlines a case of long-term peritoneal mesothelioma survival in a female patient. The patient had cytoreductive surgery. The surgery included resection of the colonic mesentery. This is tissue that is not normally part of peritoneal mesothelioma surgery. 

The case report shows the patient is still cancer-free four years after surgery with an “excellent” quality of life. 

The Challenge of Peritoneal Mesothelioma

Every year, about 2,500 Americans receive a diagnosis of mesothelioma. Peritoneal mesothelioma accounts for about a fifth of those cases. 

Most peritoneal mesothelioma patients have lived or worked around asbestos for an extended period of time. The prognosis is not usually very good. Mesothelioma tumors spread out quickly across the membrane that lines the abdomen. 

Long-term peritoneal mesothelioma survival is not common. Most patients have a life expectancy between 12 and 18 months. 

But new treatment advances are improving the odds of surviving mesothelioma. Many surgeons now follow the resection with a rinse of heated chemotherapy drugs. This is called HIPEC. It’s goal is to kill residual cells that could seed new tumors. 

Removing Key Tissues Leads to Long-Term Peritoneal Mesothelioma Survival

In his new report, Dr Sugarbaker details his new approach to removing at-risk tissue in the abdomen. The patient’s peritoneal mesothelioma treatment started with a complete cytoreductive surgery. 

“This required visceral resections, parietal peritonectomy, peritonectomy of the small bowel and its mesentery, and a peritoneal resection of the colonic mesentery with sparing of the major vasculature of the large bowel,” writes Dr. Sugarbaker in the International Journal of Surgery Case Reports.

The colonic mesentery is a double fold of peritoneal membrane. It attaches the intestine to the abdominal wall and helps hold it in place. Resection of this membrane is not a standard part of peritoneal mesothelioma surgery. 

But Dr. Sugarbaker’s success with this approach suggests that resection of the colonic mesentery, along with advanced techniques like HIPEC, has the potential to promote long-term peritoneal mesothelioma survival. 

“Malignant peritoneal mesothelioma was in the past a disease of limited survival without effective treatment options,” he writes. “A sequence of cytoreductive surgical procedures and regional chemotherapy treatments has made long-term survival possible.”

Australian Paul Kraus is an example of someone who has survived peritoneal mesothelioma for decades. Paul’s doctors told him he had just months to live but 20 years later he is still sharing his story of survival with other patients. To read about Paul’s experience of long-term peritoneal mesothelioma survival, CLICK HERE to request a free copy of his book.

Source:

Sugarbaker, P, “Peritonectomy of the colonic mesentery. Case report of a new surgical technology”, September 6, 2021, International Journal of Surgery Case Reports, Online ahead of print, https://www.sciencedirect.com/science/article/pii/S2210261221008713?via%3Dihub

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…